Invention Grant
![Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one](/docs/US/2022-02-01/US11236110B2/abs.jpg.600x600.jpg)
- Patent Title: Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
-
Application No.: US16649824Application Date: 2018-10-16
-
Publication No.: US11236110B2Publication Date: 2022-02-01
- Inventor: Carmen Almansa-Rosales , Nicolas Tesson
- Applicant: ESTEVE PHARMACEUTICALS, S.A.
- Applicant Address: ES Barcelona
- Assignee: ESTEVE PHARMACEUTICALS, S.A.
- Current Assignee: ESTEVE PHARMACEUTICALS, S.A.
- Current Assignee Address: ES Barcelona
- Agency: Hueschen and Sage
- Priority: EP17382695 20171017
- International Application: PCT/EP2018/000470 WO 20181016
- International Announcement: WO2019/076475 WO 20190425
- Main IPC: A61K31/5386
- IPC: A61K31/5386 ; A61P29/00 ; C07D498/10
![Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one](/abs-image/US/2022/02/01/US11236110B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one salts, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of sigma receptor and/or μ-opioid receptor associated disease.
Public/Granted literature
- US20200331929A1 SALTS OF (R)-9-(2,5-DIFLUOROPHENETHYL)-4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO[5.5]UNDECAN-3-ONE Public/Granted day:2020-10-22
Information query
IPC分类:
